Philadelphia business leaders address the life science industry

Dea Belazi , PharmD, MPH, CEO and co-founder, AscellaHealth

How do your end-to-end solutions for pharma/biotech manufacturers help to streamline the commercialization of specialty and rare disease therapies?

AscellaHealth’s complete end-to-end solutions for life sciences manufacturers play a pivotal role in streamlining the commercialization of medications and cell and gene therapies (CGTs) for specialty conditions and rare diseases. Pharmaceutical manufacturers turn to AscellaHealth for comprehensive and customizable programs that span the entire product lifecycle from pre-commercialization and market access strategies to exclusive distribution, international fulfillment, patient support/HUB services, comprehensive data and analytics and beyond.

To read more, click here.